Trial Profile
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALADDIN
- 15 Dec 2009 Actual end date changed from May 2006 to Mar 2007 as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.